Compare ASTRAZENECA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DIVIS LABORATORIES ASTRAZENECA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 113.7 48.1 236.3% View Chart
P/BV x 34.8 12.9 270.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DIVIS LABORATORIES
Mar-19
ASTRAZENECA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2781,639 78.0%   
Low Rs8831,115 79.2%   
Sales per share (Unadj.) Rs228.4186.3 122.6%  
Earnings per share (Unadj.) Rs10.451.0 20.3%  
Cash flow per share (Unadj.) Rs16.357.3 28.4%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs98.8261.8 37.7%  
Shares outstanding (eoy) m25.00265.47 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.77.4 64.0%   
Avg P/E ratio x104.227.0 385.7%  
P/CF ratio (eoy) x66.424.0 276.5%  
Price / Book Value ratio x10.95.3 207.9%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m27,008365,592 7.4%   
No. of employees `0001.411.8 11.4%   
Total wages/salary Rs m1,5355,423 28.3%   
Avg. sales/employee Rs Th4,210.94,175.1 100.9%   
Avg. wages/employee Rs Th1,132.2457.7 247.4%   
Avg. net profit/employee Rs Th191.11,141.8 16.7%   
INCOME DATA
Net Sales Rs m5,71049,463 11.5%  
Other income Rs m1231,556 7.9%   
Total revenues Rs m5,83351,019 11.4%   
Gross profit Rs m46318,718 2.5%  
Depreciation Rs m1471,689 8.7%   
Interest Rs m035 0.0%   
Profit before tax Rs m43818,551 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1795,023 3.6%   
Profit after tax Rs m25913,527 1.9%  
Gross profit margin %8.137.8 21.4%  
Effective tax rate %40.827.1 150.8%   
Net profit margin %4.527.3 16.6%  
BALANCE SHEET DATA
Current assets Rs m3,20946,501 6.9%   
Current liabilities Rs m2,0708,468 24.4%   
Net working cap to sales %20.076.9 26.0%  
Current ratio x1.65.5 28.2%  
Inventory Days Days72131 55.3%  
Debtors Days Days3586 40.7%  
Net fixed assets Rs m79025,797 3.1%   
Share capital Rs m50531 9.4%   
"Free" reserves Rs m2,41968,962 3.5%   
Net worth Rs m2,46969,493 3.6%   
Long term debt Rs m00-   
Total assets Rs m4,60580,383 5.7%  
Interest coverage xNM531.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 201.5%   
Return on assets %5.616.9 33.3%  
Return on equity %10.519.5 53.9%  
Return on capital %17.726.7 66.3%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m30041,238 0.7%   
Fx outflow Rs m2,01512,405 16.2%   
Net fx Rs m-1,71528,833 -5.9%   
CASH FLOW
From Operations Rs m889,543 0.9%  
From Investments Rs m-94-6,854 1.4%  
From Financial Activity Rs mNA-2,459 0.0%  
Net Cashflow Rs m-6230 -2.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 15.7 19.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   12,856 31,796 40.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Nosedived 1,939 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended deep in the red.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS